{
    "doi": "https://doi.org/10.1182/blood.V110.11.3052.3052",
    "article_title": "Effect of HLA-Matching on Outcome of Hematopoietic Stem Cell Transplantation from Unrelated Donors: A IBMDR-GITMO Study. ",
    "article_date": "November 16, 2007",
    "session_type": "Clinical Results - Alternative Donor Transplantation",
    "abstract_text": "Background HLA-matching between patient and donor is critical for outcome of haematopoietic stem cell transplantation (HSCT) performed from an unrelated donor, together with other non-HLA factors. A 10/10-matched donor is the most suitable for HSCT, when possible; however, a certain degree of HLA-incompatibility has to be accepted when such a donor is not available. Aim of the study This is a prospective multicenter GITMO study in which patients were enrolled as 6/6\u201d matched (matched at loci A, B at low resolution level and DRB1 at high resolution) or as \u201c5/6\u201d matched (one low-resolution mismatch (MM) at locus A or B). High resolution typing is now available as well. Patients. Eligible were patients with a haematological malignancy, aged > 18 years old, activating an unrelated donor search in Italy from January 1999 to June 2006. Patients with chronic myeloid leukaemia were excluded from the analysis. A total of 1069 patient-donor pairs were analyzed; median follow-up for alive pts was 23 months (range: 3\u201396). According to disease status at HSCT, pts were classified as \u201cearly\u201d ( de novo acute myeloid or lymphoblastic leukemia in first complete remission, n=241) and \u201cadvanced\u201d (all others, n=828) pts. Univariate and multivariate analysis with Cox regression included main non-HLA factors known to be associated with HSCT outcome. No differences in overall survival (OS) was observed between 5/6-matched (n=101) and 6/6-matched (n=968) pts (fig.1). There was a non-statistically significant trend toward a lower relapse-related death (RRD) in 5/6-matched compared to 6/6-matched pts was observed (5y-RRD: 18% vs 24%, respectively; p=0.13 ). We then proceeded to test the effect of the C locus: in multivariate analysis, the presence of an antigenic MM at locus C was associated with a worse OS, regardless of matching at loci A or B (RR 1.18, 95% C.I.: 1.00\u20131.40, p=0.05 ); the presence of a MM at locus B and/or C significantly affected transplant-related mortality (TRM) (RR 1.57, 95% C.I.: 1.02\u20132.44, p=0.04 ; RR 1.31, 95% C.I.: 1.04\u20131.65, p=0.02, respectively), MM at locus B or C was also associated with development of grade II-IV acute graft-versus-host disease (aGVHD) on multivariate analysis, together with \u201cnon-use\u201d of ATG (ATG use: RR 0.70, 95% C.I. 0.52\u20130.95, p=0.02 ). Conclusions , The outcome of so called 5/6 and 6/6 HLA matched unrelated donor transplants is comparable: this may be due to the fact that the C locus is not taken in to account in the \u201c5/6 or 6/6\u201d definition. Indeed a mismatch at locus C is associated with worse outcome. MM at locus B or C, but not at locus A, increases the risk of developing grade II-IV aGVHD. Use of ATG reduces aGVHD rates, thus attenuating the adverse effect of MMs at loci B and C on HSCT outcome.",
    "topics": [
        "donors",
        "hematopoietic stem cell transplantation",
        "human leukocyte antigens",
        "brachial plexus neuritis",
        "adverse effects",
        "complete remission",
        "follow-up",
        "graft-versus-host disease, acute",
        "hematologic neoplasms",
        "leukemia, myelocytic, chronic"
    ],
    "author_names": [
        "Roberto Crocchiolo, MD",
        "Fabio Ciceri, MD",
        "Rosa Oneto, MD",
        "Barbara Bruno, MD",
        "Simona Pollichieni, MD",
        "Nicoletta Sacchi, MD",
        "Maria Pia Sormani, MD",
        "Renato Fanin, MD",
        "Giuseppe Bandini, MD",
        "Alberto Bosi, MD",
        "Alessandro Rambaldi, MD",
        "Paolo Emilio Alessandrino, MD",
        "Michele Falda, MD",
        "Andrea Bacigalupo, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Roberto Crocchiolo, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Fabio Ciceri, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rosa Oneto, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Barbara Bruno, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Simona Pollichieni, MD",
            "author_affiliations": [
                "IBMDR, Italian Bone Marrow Donor Registry"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicoletta Sacchi, MD",
            "author_affiliations": [
                "IBMDR, Italian Bone Marrow Donor Registry"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Pia Sormani, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Renato Fanin, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe Bandini, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alberto Bosi, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandro Rambaldi, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paolo Emilio Alessandrino, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Falda, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Bacigalupo, MD",
            "author_affiliations": [
                "GITMO, Gruppo Italiano Trapianto di Midollo Osseo"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-05T09:34:53",
    "is_scraped": "1"
}